Alkermes (ALKS) Tops Q3 EPS by 15c, Revenues Beat; Raises FY18 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Alkermes (ALKS) PT Lowered to $47 at Credit Suisse
October 24, 2018 8:54 AM EDTCredit Suisse analyst Vamil Divan lowered the price target on Alkermes (NASDAQ: ALKS) to $47.00 (from $51.00) while maintaining an Outperform rating following Q3.
Divan modestly reduces their sales estimates for Vivitrol and Aristada and also increase some of their expense assumptions... More
